Dr Suzanne Lentzsch talks to ecancer about her LINKER-MM1 trial.

The LINKER-MM1 Phase 1/2 clinical trial investigated 200 mg linvoseltamab, a bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

Results showed a high objective response rate (71%), with deep and durable responses, including a ≥VGPR rate of 62% and a ≥CR rate of 46%.

Long-term follow-up indicated sustained efficacy, with a 12-month probability of maintaining response at 78% for all responders and 92% for patients with ≥CR.

The treatment was generally manageable, with the most common adverse events being cytokine release syndrome, neutropenia, and anemia.

The study highlights linvoseltamab's potential as a highly effective treatment for RRMM, including in high-risk subgroups.